These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33774750)

  • 1. Long-term outcomes and prognostic factors in generalized myasthenia gravis.
    Ozawa Y; Uzawa A; Yasuda M; Kojima Y; Onishi Y; Oda F; Kanai T; Himuro K; Kawaguchi N; Kuwabara S
    J Neurol; 2021 Oct; 268(10):3781-3788. PubMed ID: 33774750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal symptom expression achievement over time in generalized myasthenia gravis.
    Uzawa A; Ozawa Y; Yasuda M; Onishi Y; Akamine H; Kuwabara S
    Acta Neurol Belg; 2023 Jun; 123(3):979-982. PubMed ID: 36592291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Less is not necessarily more: low-dose corticosteroid therapy and long-term prognosis in generalized myasthenia gravis after thymectomy.
    Zhang Y; Li F; Zhu H; Yu H; Wang T; Yan X
    Neurol Sci; 2022 Jun; 43(6):3949-3956. PubMed ID: 35043357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adequate tacrolimus concentration for myasthenia gravis treatment.
    Kanai T; Uzawa A; Kawaguchi N; Himuro K; Oda F; Ozawa Y; Kuwabara S
    Eur J Neurol; 2017 Feb; 24(2):270-275. PubMed ID: 28102047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan.
    Imai T; Utsugisawa K; Murai H; Tsuda E; Nagane Y; Suzuki Y; Minami N; Uzawa A; Kawaguchi N; Masuda M; Konno S; Suzuki H; Akaishi T; Aoki M
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):513-517. PubMed ID: 29175893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
    Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
    JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis.
    Ozawa Y; Uzawa A; Kanai T; Oda F; Yasuda M; Kawaguchi N; Himuro K; Kuwabara S
    J Neurol Sci; 2019 Jul; 402():12-15. PubMed ID: 31100651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis.
    Mee J; Paine M; Byrne E; King J; Reardon K; O'Day J
    J Neuroophthalmol; 2003 Dec; 23(4):251-5. PubMed ID: 14663303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis.
    Isshiki Y; Mimura O; Gomi F
    Jpn J Ophthalmol; 2020 Nov; 64(6):628-634. PubMed ID: 32936398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis.
    Zhao R; Wang Y; Huan X; Zhong H; Zhou Z; Xi J; Da Y; Lei L; Chang T; Ruan Z; Luo L; Li S; Yang H; Li Y; Luo S; Zhao C
    J Transl Med; 2021 Jun; 19(1):285. PubMed ID: 34193193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
    Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
    J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral corticosteroid therapy and present disease status in myasthenia gravis.
    Imai T; Suzuki S; Tsuda E; Nagane Y; Murai H; Masuda M; Konno S; Suzuki Y; Nakane S; Fujihara K; Suzuki N; Utsugisawa K
    Muscle Nerve; 2015 May; 51(5):692-6. PubMed ID: 25155615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
    Datta S; Singh S; Govindarajan R
    J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation between oral corticosteroid therapy and present disease status in myasthenia gravis].
    Imai T
    Rinsho Shinkeigaku; 2013; 53(11):1306-8. PubMed ID: 24291969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis.
    Duan W; Peng Y; Jin W; Ouyang S; Yang H
    J Immunol Res; 2021; 2021():9138548. PubMed ID: 34845439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.
    Ruan Z; Tang Y; Gao T; Li C; Guo R; Sun C; Huang X; Li Z; Chang T
    CNS Neurosci Ther; 2024 Jun; 30(6):e14793. PubMed ID: 38894580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
    Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
    J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.